BR0206112A - Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina - Google Patents

Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina

Info

Publication number
BR0206112A
BR0206112A BR0206112-0A BR0206112A BR0206112A BR 0206112 A BR0206112 A BR 0206112A BR 0206112 A BR0206112 A BR 0206112A BR 0206112 A BR0206112 A BR 0206112A
Authority
BR
Brazil
Prior art keywords
nucleic acid
encoding nucleic
cytokine
tumor antigen
vaccines
Prior art date
Application number
BR0206112-0A
Other languages
English (en)
Inventor
Linda Snyder
Bernard Scallon
David M Knight
Stephen G Mccarthy
Theresa J Goletz
Patrick J Branigan
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of BR0206112A publication Critical patent/BR0206112A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Abstract

"VACINAS DE áCIDO NUCLéICO USANDO áCIDOS NUCLéICOS DE CODIFICAçãO DE ANTìGENO DE TUMOR COM áCIDO NUCLéICO DE CODIFICAçãO DE AUXILIAR DE CITOCINA". Vacinas de ácido nucléico são providas que compreendem pelo menos um ácido nucléico de codificação de antígeno de tumor e pelo menos um ácido nucléico de codificação de auxiliar de citocina para profilaxia ou tratamento de tumores. As vacinas virais da invenção são opcionalmente combinadas ou adicionalmente administradas com um vírus recombinante ou reforçador de vacina de DNA.
BR0206112-0A 2001-10-10 2002-09-18 Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina BR0206112A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32837101P 2001-10-10 2001-10-10
PCT/US2002/029640 WO2003031569A2 (en) 2001-10-10 2002-09-18 Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid

Publications (1)

Publication Number Publication Date
BR0206112A true BR0206112A (pt) 2005-05-10

Family

ID=23280723

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206112-0A BR0206112A (pt) 2001-10-10 2002-09-18 Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina

Country Status (7)

Country Link
US (1) US20050261213A1 (pt)
EP (1) EP1507540A4 (pt)
AR (1) AR036793A1 (pt)
AU (1) AU2002326961A1 (pt)
BR (1) BR0206112A (pt)
NO (1) NO20032586L (pt)
WO (1) WO2003031569A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US8716254B2 (en) * 2003-03-24 2014-05-06 The Scripps Research Institute DNA vaccines against tumor growth and methods of use thereof
EP1687322B1 (en) 2003-11-12 2017-02-08 The Government of the United States of America, represented by the Secretary, Department of Health and Human Services Custom vectors for treating and preventing pancreatic cancer
CA2545164C (en) * 2003-11-12 2016-11-29 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Recombinant vectors expressing mucin and carcinoembryoinic antigen
DK1839120T3 (da) 2004-12-21 2013-11-11 Janssen Biotech Inc Vektorer baseret på Anti-IL-12-antistoffer, værtsceller og fremgangsmåder til fremstilling og anvendelser
US20080226619A1 (en) 2005-01-28 2008-09-18 Ramot At Tel Aviv University, Ltd. Anti-Muc1 Alpha/Beta Antibodies
KR102006527B1 (ko) * 2013-11-01 2019-08-02 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
CN110114086A (zh) * 2016-06-03 2019-08-09 埃特彼塞斯公司 用于使用前列腺癌相关抗原肿瘤疫苗接种的组合物和方法
WO2019155833A1 (ja) * 2018-02-07 2019-08-15 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター
CN108624691A (zh) * 2018-06-22 2018-10-09 杭州西合精准医疗科技有限公司 一种用于判断前列腺疾病的标志物及其应用
BR112023003834A2 (pt) * 2020-09-02 2023-03-28 4D Molecular Therapeutics Inc Genes rpgrorf15 otimizados por códon e usos dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013268A (en) * 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
AU4224599A (en) * 1998-05-29 1999-12-13 Trustees Of The University Of Pennsylvania, The Anti-prostate cancer vaccines, and methods of making, using and evaluating the same
US6387888B1 (en) * 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US6495130B1 (en) * 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
AU2002239441A1 (en) * 2000-11-01 2002-05-27 American Foundation For Biological Research, Inc. Methods and compositions for inducing cell-mediated immune responses

Also Published As

Publication number Publication date
WO2003031569A3 (en) 2004-12-29
WO2003031569A2 (en) 2003-04-17
AR036793A1 (es) 2004-10-06
EP1507540A2 (en) 2005-02-23
AU2002326961A1 (en) 2003-04-22
NO20032586D0 (no) 2003-06-06
US20050261213A1 (en) 2005-11-24
EP1507540A4 (en) 2006-12-06
NO20032586L (no) 2003-08-04

Similar Documents

Publication Publication Date Title
CY1115405T1 (el) Αλληλουχιες κυκλοϊου που συνδyαζονται με την ασθενεια της καχεξιας του χοιριδιου (map)
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
BR0206112A (pt) Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
NO20013701L (no) HER-2/neu-fusjonsproteiner
HK1153761A1 (en) Cancer antigens based on products of the tumor suppressor gene wt1 wt1
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
DE69519521T2 (de) Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
WO2004050856A3 (en) Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
WO2002022686A3 (en) Defensin-antigen fusion proteins
NO944245L (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
BR9909342A (pt) Vacinas adn adjuvadas
ATE285239T1 (de) Dna enthaltende impfstoffen
DK1536006T3 (da) Cancerantigener og anvendelse deraf
DE60127715D1 (de) Polypeptide zur auslösung einer immunreaktion gegen krebs
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
AU6683400A (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
FR2828405B1 (fr) Vaccin anti-coronavirus
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
CY1105947T1 (el) Νουκλεϊνικα οξεα και πρωτεϊνες του γονιδιου mhp3 του mycoplasma hyopneumoniae και χρησεις αυτων
WO2003093298A3 (en) Immunogenic peptides
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: CENTOCOR, INC

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]